ARCANE investigates shipping data, contracts, filings and policy documents, shows you the evidence, makes a dated call, and keeps score in public.
Every claim links to the source it came from.
Each article says what should happen next, by when, and what would prove it wrong.
Every call is scored as it resolves.
First Brands' collapse exposed multiple lenders with claims on the same receivables after the auto parts supplier sold identical invoices to different financiers over years.
Both companies reported increased sales and raised their outlooks, but investor focus shifted to price competition rather than prescription volume.
The ships are still moving, just not through the lanes anyone expected at the start of the year.
Beijing cut the metal, Tokyo kept the factories, and now the magnet makers are spending their own stockpiles to hold the line.
A site no inspector has ever entered is the only nuclear location in Iran still being built, and that fact is the whole story.
An ally's currency defense has become America's bond-market shield, and each rescue makes the next one harder.
Barges that once moved Germany’s industry now run nearly empty, raising costs faster than new orders arrive.
The mechanism runs through inventory capacity: when dealers cannot warehouse new debt, issuers pay more to clear it.
Borrowers that need continuous access to new debt face pressure sooner than companies funded through longer-term loans.
Procurement, insurance and longer shipping routes draw cash from operators before reported revenue catches up.
The continent spent the last winter's savings to stay warm through the ban it wrote itself, and now the calendar is doing what Russia never could.
The brands are being culled before the companies are, and every shelved prototype is an admission the volume was never coming back.
Regions are views over one intelligence corpus, not separate desks.
AXT’s unresolved August approvals make the next filing window decisive for whether funded capacity becomes usable supply for U.S. buyers.
India’s use of late-stage foreign data and domestic trials lets hospitals offer new therapies before OECD regulators complete their review.
Record backlogs and misaligned contract schedules have decoupled DRAM price signals from real inventory flows, raising risk for both sides until new supply arrives.
Defense and industrial stocks rise on new contract awards, with trading responding to public disclosures weeks before changes appear in official forecasts or guidance statements.